Multiple Myeloma Market Outlook To 2033

Report forecasts the multiple myeloma market to reach $40.41B by 2033 (from $21.78B in 2024), driven by rising cases and therapy advances.

Published on August 27, 2025

myeloma
Multiple myeloma, also known as myeloma, is a type of bone marrow cancer. Bone marrow is the spongy tissue at the centre of some bones that produces the body`s blood cells. It`s called multiple myeloma as the cancer often affects several areas of the body, such as the spine, skull, pelvis and ribs.

A new report from ResearchAndMarkets.com, “Multiple Myeloma Market Size and Share Analysis – Growth Trends and Forecast Report 2025–2033,” outlines steady global growth for multiple myeloma therapies through 2033.

Market Snapshot

  • 2024 market value: USD 21.78 billion
  • 2033 forecast: USD 40.41 billion
  • CAGR during the forecast window: 7.11%

What’s Driving Growth

  • Rising prevalence: cases are increasing worldwide, especially among older adults. The release cites factors such as genetic susceptibility, exposure to toxic chemicals, and lifestyle changes.
  • Therapeutic advances: targeted therapies (including monoclonal antibodies and proteasome inhibitors) and immunotherapies like CAR-T cell therapy are improving outcomes and gaining adoption.
  • More research and access: increased oncology R&D, better diagnostics, and wider availability of healthcare facilities are supporting uptake.
  • Regional momentum: growing awareness and improved diagnosis are boosting therapy use across the U.S., Europe, and Asia-Pacific. Pharmaceutical investment and government funding are also expanding treatment availability.

Challenges To Watch

  • High costs: targeted agents, immunotherapies, stem cell/bone marrow transplants, and maintenance therapy are expensive, limiting access in many regions even where reimbursement exists.
  • Side effects and resistance: patients may develop resistance over time, requiring therapy changes. Reported side effects include infections, fatigue, and organ injury, which can affect quality of life.

Treatment Landscape At A Glance

  • Common approaches include chemotherapy, immunotherapy, targeted therapies, corticosteroids, and stem cell transplants.
  • The release highlights growing use of monoclonal antibodies and CAR-T therapies worldwide.

The report points to a growing global market for multiple myeloma treatments through 2033, driven by rising case detection, broader access, and advances in targeted and immune-based therapies. Cost, side effects, and resistance remain meaningful constraints that shape adoption and patient experience.

Get the latest insurance market updates and discover exclusive program opportunities at ProgramBusiness.com. 

Are you a retail Agent Looking for a Quote?